Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: A direct comparison study

Jin Young Shin, Hyun Jung Park, Young Hwan Ahn, Phil Hyu Lee

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa (l-dopa) and dopamine agonists have been most commonly used for symptomatic treatment. However, there are discrepancies between clinical and experimental data with respect to the neuroprotective effects of these drugs on dopaminergic neurons. In this study, to determine whether l-dopa is toxic or dopamine agonist is neuroprotective to dopaminergic neurons, we evaluated the neuroprotective properties of l-dopa and the pramipexol (PPX), one of dopamine agonists, with a focus on the regulatory effects of the anti-oxidant properties and cell survival or apoptotic signal pathways in the same experimental design, using 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated PD animals. The glutathione level in MPTP-treated mice was significantly increased by PPX administration but not by L-dopa treatment. The expression of phosphorylated extracellular signal regulated kinase in MPTP-treated mice was significantly increased only with l-dopa treatment. Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice. Immunohistochemical analysis showed that both l-dopa and PPX increased significantly survival of dopaminergic neurons in MPTP-treated mice. Our study demonstrated that both l-dopa and PPX had comparable neuroprotective properties for dopaminergic neurons in MPTP-treated PD animal models, through modulation of cell survival and apoptotic pathways.

Original languageEnglish
Pages (from-to)1042-1050
Number of pages9
JournalJournal of Neurochemistry
Volume111
Issue number4
DOIs
Publication statusPublished - 2009 Nov 1

Fingerprint

Dihydroxyphenylalanine
Dopaminergic Neurons
Neuroprotective Agents
Neurons
Parkinson Disease
Animals
Animal Models
Dopamine Agonists
Levodopa
Cell Survival
Cells
Neurodegenerative diseases
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Phosphorylation
Poisons
Extracellular Signal-Regulated MAP Kinases
Cytochromes c
4-phenyl-1,2,3,6-tetrahydropyridine
pramipexole
Oxidants

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

@article{b7b2068275f148239ad757fdcb27ed80,
title = "Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: A direct comparison study",
abstract = "Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa (l-dopa) and dopamine agonists have been most commonly used for symptomatic treatment. However, there are discrepancies between clinical and experimental data with respect to the neuroprotective effects of these drugs on dopaminergic neurons. In this study, to determine whether l-dopa is toxic or dopamine agonist is neuroprotective to dopaminergic neurons, we evaluated the neuroprotective properties of l-dopa and the pramipexol (PPX), one of dopamine agonists, with a focus on the regulatory effects of the anti-oxidant properties and cell survival or apoptotic signal pathways in the same experimental design, using 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated PD animals. The glutathione level in MPTP-treated mice was significantly increased by PPX administration but not by L-dopa treatment. The expression of phosphorylated extracellular signal regulated kinase in MPTP-treated mice was significantly increased only with l-dopa treatment. Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice. Immunohistochemical analysis showed that both l-dopa and PPX increased significantly survival of dopaminergic neurons in MPTP-treated mice. Our study demonstrated that both l-dopa and PPX had comparable neuroprotective properties for dopaminergic neurons in MPTP-treated PD animal models, through modulation of cell survival and apoptotic pathways.",
author = "Shin, {Jin Young} and Park, {Hyun Jung} and Ahn, {Young Hwan} and Lee, {Phil Hyu}",
year = "2009",
month = "11",
day = "1",
doi = "10.1111/j.1471-4159.2009.06381.x",
language = "English",
volume = "111",
pages = "1042--1050",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "4",

}

Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease : A direct comparison study. / Shin, Jin Young; Park, Hyun Jung; Ahn, Young Hwan; Lee, Phil Hyu.

In: Journal of Neurochemistry, Vol. 111, No. 4, 01.11.2009, p. 1042-1050.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease

T2 - A direct comparison study

AU - Shin, Jin Young

AU - Park, Hyun Jung

AU - Ahn, Young Hwan

AU - Lee, Phil Hyu

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa (l-dopa) and dopamine agonists have been most commonly used for symptomatic treatment. However, there are discrepancies between clinical and experimental data with respect to the neuroprotective effects of these drugs on dopaminergic neurons. In this study, to determine whether l-dopa is toxic or dopamine agonist is neuroprotective to dopaminergic neurons, we evaluated the neuroprotective properties of l-dopa and the pramipexol (PPX), one of dopamine agonists, with a focus on the regulatory effects of the anti-oxidant properties and cell survival or apoptotic signal pathways in the same experimental design, using 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated PD animals. The glutathione level in MPTP-treated mice was significantly increased by PPX administration but not by L-dopa treatment. The expression of phosphorylated extracellular signal regulated kinase in MPTP-treated mice was significantly increased only with l-dopa treatment. Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice. Immunohistochemical analysis showed that both l-dopa and PPX increased significantly survival of dopaminergic neurons in MPTP-treated mice. Our study demonstrated that both l-dopa and PPX had comparable neuroprotective properties for dopaminergic neurons in MPTP-treated PD animal models, through modulation of cell survival and apoptotic pathways.

AB - Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa (l-dopa) and dopamine agonists have been most commonly used for symptomatic treatment. However, there are discrepancies between clinical and experimental data with respect to the neuroprotective effects of these drugs on dopaminergic neurons. In this study, to determine whether l-dopa is toxic or dopamine agonist is neuroprotective to dopaminergic neurons, we evaluated the neuroprotective properties of l-dopa and the pramipexol (PPX), one of dopamine agonists, with a focus on the regulatory effects of the anti-oxidant properties and cell survival or apoptotic signal pathways in the same experimental design, using 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated PD animals. The glutathione level in MPTP-treated mice was significantly increased by PPX administration but not by L-dopa treatment. The expression of phosphorylated extracellular signal regulated kinase in MPTP-treated mice was significantly increased only with l-dopa treatment. Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice. Immunohistochemical analysis showed that both l-dopa and PPX increased significantly survival of dopaminergic neurons in MPTP-treated mice. Our study demonstrated that both l-dopa and PPX had comparable neuroprotective properties for dopaminergic neurons in MPTP-treated PD animal models, through modulation of cell survival and apoptotic pathways.

UR - http://www.scopus.com/inward/record.url?scp=70350134171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350134171&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2009.06381.x

DO - 10.1111/j.1471-4159.2009.06381.x

M3 - Article

C2 - 19765187

AN - SCOPUS:70350134171

VL - 111

SP - 1042

EP - 1050

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 4

ER -